Ticker history: INM became MTRI (Mentari Therapeutics, Inc.) on . Earlier news and filings retain their original names and dates. View INM history.
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the filing for Q1 FY2027, filed Nov 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MTRI SEC filings page.
This page shows Mentari Therapeutics, Inc. (MTRI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
Financial Health Signals
We do not publish a peer-relative financial health score for Mentari Therapeutics, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Mentari Therapeutics, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Mentari Therapeutics, Inc. reported a net loss of $12.6M while operations used $8.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Mentari Therapeutics, Inc. reported a net loss of $2.3M in Q1 2027. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Mentari Therapeutics, Inc. earned -$0.42 per diluted share (EPS) in Q1 2027. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q1 2027.
Not reported for Q1 2027.
Cash & Balance Sheet
Mentari Therapeutics, Inc. held $1.1M in cash as of Q1 2027; no long-term debt figure is on record for that period.
Not reported for Q1 2027.
Not reported for Q1 2027.
Margins & Returns
None of these metrics is reported for Q1 2027.
Capital Allocation
Mentari Therapeutics, Inc. invested $206K in research and development in Q1 2027. This represents a decrease of 64.2% from the same quarter a year earlier. Against the prior quarter it is down 74.2%.
Not reported for Q1 2027.
Not reported for Q1 2027.
MTRI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'27Filing | Q4'26Filing | Q3'26Filing | Q2'26Filing | Q1'26Filing | Q4'25Filing | Q3'25Filing | Q2'25Filing |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $820K-26.2% | $1.1M-11.4% | $1.3M+1.7% | $1.3M+7.6% | $1.1M-10.4% |
| Cost of Revenue | N/A | N/A | N/A | $636K-2.3% | $717K-7.0% | $728K | $1.1M+23.0% | $651K-29.0% |
| Gross Profit | N/A | N/A | N/A | $184K-60.0% | $403K-18.3% | $577K+23.7% | $176K-39.3% | $461K+42.2% |
| R&D Expenses | $206K-64.2% | $800K-0.1% | $1.0M+140.4% | $631K-29.6% | $575K-17.8% | $801K+21.5% | $425K-35.2% | $895K+46.8% |
| SG&A Expenses | $1.8M+45.6% | $2.1M-8.6% | $1.7M+9.9% | $1.6M-5.7% | $1.2M-17.0% | $2.3M+27.9% | $1.6M+15.3% | $1.7M+26.0% |
| Net Income | -$2.3Mn/m | -$5.8Mn/m | -$3.0Mn/m | -$2.0Mn/m | -$1.7Mn/m | -$1.8Mn/m | -$2.1Mn/m | -$2.6Mn/m |
| EPS (Basic) | -$0.42 | -$1.43 | -$0.73 | -$0.51 | -$0.44 | -$0.43 | -$1.94 | -$3.64 |
| EPS (Diluted) | -$0.42 | -$1.43 | -$0.73 | -$0.51 | -$0.44 | -$0.43 | -$1.94 | -$3.64 |
| Diluted Shares (Avg) | 5M | N/A | 4M | 4M | 4M | N/A | 1M | 706,546 |
Not reported in any period shown, so not listed: Operating Income, EBITDA, Interest Expense, Income Tax.
MTRI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'27Filing | Q4'26Filing | Q3'26Filing | Q2'26Filing | Q1'26Filing | Q4'25Filing | Q3'25Filing | Q2'25Filing |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.3M-90.2% | $3.0M-80.6% | $9.1M-1.6% | $11.2M+31.6% | $13.4M+27.7% | $15.6M+31.8% | $9.3M | $8.5M-44.3% |
| Current Assets | $1.3M-88.3% | $2.7M-79.2% | $6.9M+7.5% | $8.8M+60.7% | $10.8M+48.4% | $12.9M+48.1% | $6.4M | $5.5M-53.7% |
| Cash & Equivalents | $1.1M-88.3% | $2.2M-79.6% | $5.2M+10.2% | $7.0M+103.4% | $9.3M+67.1% | $10.7M+63.5% | $4.7M-38.4% | $3.4M-64.1% |
| Short-Term Investments | $40K-5.9% | $40K-8.6% | $42K+2.6% | $43K+4.6% | $43K-0.8% | $43K+0.7% | $41Kn/m | $41K-8.3% |
| Inventory | N/A | N/A | N/A | $948K-14.1% | $891K-27.0% | $961K-22.8% | $814K | $1.1M+48.1% |
| Accounts Receivable | N/A | N/A | N/A | $183K-30.3% | $343K+20.6% | $465K+31.8% | $368K | $263K-29.6% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $2.5M+41.5% | $2.0M-8.9% | $2.2M-0.7% | $1.6M-30.9% | $1.8M-14.5% | $2.1M-18.0% | $2.3M | $2.3M-6.6% |
| Current Liabilities | N/A | $2.0M+6.3% | $2.2M+20.2% | $1.5M-17.4% | $1.6M+8.3% | $1.8M-6.7% | $1.8M | $1.8M+6.6% |
| Non-Current Liabilities | N/A | $0-100.0% | $31K-92.7% | $124K-76.6% | $215K-66.0% | $306K-52.6% | $419K | $529K-34.1% |
| Total Equity | -$1.2M-110.3% | $1.1M-92.0% | $6.9M-1.8% | $9.6M+55.1% | $11.6M+38.1% | $13.4M+45.9% | $7.0M-36.8% | $6.2M-51.6% |
| Retained Earnings | -$132.6Mn/m | -$130.2Mn/m | -$124.0Mn/m | -$121.0Mn/m | -$119.0Mn/m | -$117.2Mn/m | -$115.4M | -$113.3Mn/m |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
MTRI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'27Filing | Q4'26Filing | Q3'26Filing | Q2'26Filing | Q1'26Filing | Q4'25Filing | Q3'25Filing | Q2'25Filing |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.1Mn/m | -$3.0Mn/m | -$1.7Mn/m | -$2.1Mn/m | -$1.9Mn/m | -$2.1Mn/m | -$1.7Mn/m | -$2.5Mn/m |
| Depreciation & Amortization | $168-99.7% | $48K-8.3% | $51K-3.4% | $53K0.0% | $53K-2.5% | $53K-3.7% | $52K-4.5% | $53K-3.7% |
| Stock-Based Compensation | $16K-19.0% | N/A | $39K-4.2% | $26K+10.4% | $20K-30.2% | N/A | $40K-26.9% | $23K+26.8% |
| Investing Cash Flow | $2K | $0n/m | N/A | N/A | N/A | $0n/m | N/A | N/A |
| Financing Cash Flow | $40Kn/m | -$1-100.0% | $232K-92.1% | $0-100.0% | -$137K-116.4% | $8.2M+4644531.3% | $2.9Mn/m | $339K |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
MTRI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'27Filing | Q4'26Filing | Q3'26Filing | Q2'26Filing | Q1'26Filing | Q4'25Filing | Q3'25Filing | Q2'25Filing |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | 22.5%-19.0pp | 36.0%-3.0pp | 44.2%+7.9pp | 13.9%-10.8pp | 41.5%+15.3pp |
| Net Margin | N/A | N/A | N/A | -247.3% | -154.2% | -137.1% | -168.1% | -231.6% |
| Return on Equity | N/A | -543.2%-529.9pp | -43.0%-12.8pp | -21.1%+20.5pp | -14.9%+5.1pp | -13.3%+7.7pp | -30.2%-14.7pp | -41.6%-30.1pp |
| Return on Assets | -178.5%-165.6pp | -192.7%-181.2pp | -32.5%-9.6pp | -18.1%+12.2pp | -12.9%+3.1pp | -11.5%+4.9pp | -22.9% | -30.3%-20.6pp |
| Current Ratio | N/A | 1.37-5.6x | 3.12-0.4x | 5.94+2.9x | 6.95+1.9x | 6.99+2.6x | 3.49 | 3.05-4.0x |
| Liabilities-to-Equity | N/A | 1.82+1.7x | 0.330.0x | 0.17-0.2x | 0.15-0.1x | 0.16-0.1x | 0.32 | 0.38+0.2x |
| Asset Turnover | N/A | N/A | N/A | 0.07-0.1x | 0.080.0x | 0.080.0x | 0.14 | 0.130.0x |
Not reported in any period shown, so not listed: Operating Margin, Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Mentari Therapeutics, Inc. MTRI | FY2026 | N/A | -$12.6M | N/A | $856.9M | — |
| Immatics N.V. IMTX | FY2025 | $56.6M | -$230.6M | N/A | $878.6M | 55/100 |
| Latigo Biotherapeutics, Inc. LTGO | FY2025 | N/A | N/A | N/A | $861.9M | — |
| Pharming Group N.V. PHAR | FY2025 | $376.1M | $2.9M | 0.8% | $816.8M | 61/100 |
| Corvus Pharmaceuticals, Inc. CRVS | FY2025 | N/A | -$15.3M | N/A | $815.7M | — |
| MoonLake Immunotherapeutics MLTX | FY2025 | N/A | -$227.3M | N/A | $942.1M | — |
Where Mentari Therapeutics, Inc. Ranks
Frequently Asked Questions
No, Mentari Therapeutics, Inc. (MTRI) reported a net loss of $13.2M over the trailing 12 months to September 30, 2026. In fiscal year 2026 it reported a net loss of $12.6M.
Mentari Therapeutics, Inc. (MTRI) has a return on equity of -1168.4% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
Mentari Therapeutics, Inc. (MTRI) recorded an outflow of $8.6M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
Mentari Therapeutics, Inc. (MTRI) had $3.0M in total assets as of fiscal year 2026, including both current and long-term assets.
Mentari Therapeutics, Inc. (MTRI) invested $3.0M in research and development during fiscal year 2026.
Mentari Therapeutics, Inc. (MTRI) had a current ratio of 1.37 as of fiscal year 2026, which is considered adequate.
Mentari Therapeutics, Inc. (MTRI) had a liabilities-to-equity ratio of 1.82 as of fiscal year 2026, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2026, because the filing data we hold for that year carries no long-term debt figure.
Mentari Therapeutics, Inc. (MTRI) had a return on assets of -414.5% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
Mentari Therapeutics, Inc. (MTRI) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $856.9M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Mentari Therapeutics, Inc. (MTRI) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $856.9M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2026, Mentari Therapeutics, Inc. (MTRI) held $2.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.6M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Mentari Therapeutics, Inc. (MTRI) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Mentari Therapeutics, Inc. (MTRI) reported a net loss of $12.6M while operations used $8.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.